Chunlizhengda Medical Instruments reports strong Q3 growth, profit surges 213%

Beijing Chunlizhengda Medical Instruments Co., Ltd. announced a robust performance for the nine months ended September 30, 2025, with revenue climbing to 756,093,897.40 yuan, a 48.75% increase from the prior year. Net profit attributable to shareholders surged by 213.21% to 191,531,404.47 yuan. Basic and diluted earnings per share also saw substantial growth, both rising by 212.50% to 0.50 yuan per share. These gains are attributed to product lines entering a new growth phase post-centralized procurement, coupled with a dual strategy of product innovation and international expansion.

The company's gross profit experienced a 220.09% increase, reaching 211,788,696.95 yuan. Net cash flows generated from operating activities amounted to 174,567,044.11 yuan for the nine-month period. Total assets stood at 3,540,324,901.27 yuan, marking a 2.15% increase since the end of last year, while owners' equity attributable to shareholders grew by 5.84% to 2,984,717,139.32 yuan.

The board proposes a cash dividend of 2.10 yuan (tax inclusive) for every 10 shares, totaling 80,260,246.29 yuan, which represents 41.90% of the net profit attributable to ordinary shareholders in the consolidated statement. This plan is subject to approval at the 2025 First Extraordinary General Meeting.